SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
InnaVirVax: the Phase I/IIa Clinical Study of Its VAC-3S Immunotherapeutic Vaccine in the Treatment of HIV Infection Has Achieved Its Primary Endpoint